> > >

Ensure Your
Patients Receive
At The
Lowest Available

ANNOVERA Is Covered By
The Majority Of Health Plans

Most Patients Pay $0

Savings Program

The ANNOVERA Patient Savings Program is
available to help ensure patients with a
copayment responsibility who have met their
deductible pay as little as $0 for a full year of

MAYNE Annovera Copay Card

Download the copay card today.


For eligible patients with a copayment responsibility who have met their deductible. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see Program Terms, Conditions, and Eligibility Criteria.

Prescribe ANNOVERA

ePrescribe to GoodRx to help simplify the prescription experience and
ensure the most affordable price.

To ePrescribe to GoodRx Prescription Services select:

GoodRx Prescription Services
[in Orlando, FL 32809]
NCPDP #575523 or FAX prescription to:

When you ePrescribe to GoodRx, a Customer Care Advocate will reach out to your
patients within 24-48 hours to offer:

  • Insurance benefit verification & assurance of the most affordable price
  • Answers to product-related questions
  • Convenient options for pick-up at their local pharmacy or home delivery


Connect With Us

844-ANNOVERA (877-219-7537)


Sample Letter of
Medical Necessity

Birth control coverage is mandated under the Affordable Care Act (ACA): The ACA mandates that most private health plans must cover all FDA-approved classes of contraceptive methods.

For your patients not covered or in a plan with a high deductible, a letter of medical necessity can assist in securing coverage with no copayment.

To help your patients with access and reimbursement, download the Sample Letter below, complete, and email along with a prescription to your patient's preferred pharmacy.

Download letter now



See full prescribing information for complete boxed warning.

  • Females over 35 years old who smoke should not use ANNOVERA.
  • Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use.


ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is contraindicated and should not be used in women with a high risk of arterial or venous thrombotic diseases; current or history of breast cancer or other estrogen- or progestin-sensitive cancer; liver tumors, acute hepatitis, or severe (decompensated) cirrhosis; undiagnosed abnormal uterine bleeding; hypersensitivity to any of the components of ANNOVERA; and use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.


  • Stop ANNOVERA if a thrombotic or thromboembolic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Start ANNOVERA no earlier than 4 weeks after delivery, in females who are not breastfeeding. Consider cardiovascular risk factors before initiating in all females, particularly those over 35 years.
  • Discontinue if jaundice occurs.
  • Stop ANNOVERA prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir. ANNOVERA can be restarted 2 weeks following completion of this regimen.
  • Do not prescribe ANNOVERA for females with uncontrolled hypertension or hypertension with vascular disease. Monitor blood pressure and stop use if blood pressure rises significantly in females with well-controlled hypertension.
  • Monitor glucose in pre-diabetic or diabetic females taking ANNOVERA. Consider an alternate contraceptive method for females with uncontrolled dyslipidemias.
  • Patients using ANNOVERA who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. ANNOVERA should be discontinued if indicated.
  • Other warnings include: gallbladder disease; depression; cervical cancer; increased serum concentrations of binding globulins; hereditary angioedema; chloasma (females who tend to develop chloasma should avoid exposure to the sun or UV radiation while using ANNOVERA); toxic shock syndrome (TSS) (if a patient exhibits symptoms of TSS, remove ANNOVERA, and initiate appropriate medical treatment); vaginal use (ANNOVERA may not be suitable for females with conditions that make the vagina more susceptible to vaginal irritation or ulceration).


The most common adverse reactions reported in at least 5% of women who received ANNOVERA were: headache/migraine, nausea/vomiting, vulvovaginal mycotic infection/candidiasis, lower/upper abdominal pain, dysmenorrhea, vaginal discharge, urinary tract infection, breast pain/tenderness/discomfort, bleeding irregularities including metrorrhagia, diarrhea, and genital pruritus.


Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of ANNOVERA or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with ANNOVERA.


ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is a progestin/estrogen combination hormonal contraceptive indicated for use by females of reproductive potential to prevent pregnancy.

Limitations of Use: ANNOVERA has not been adequately studied in females with a body mass index >29 kg/m2.

Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING.

Please Wait